Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial of BioChaperone Lispro in patients with type 1 diabetes mellitus

Trial Profile

Phase III trial of BioChaperone Lispro in patients with type 1 diabetes mellitus

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin lispro (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Adocia
  • Most Recent Events

    • 14 Oct 2021 According to an Adocia media release, the application of phase 3 clinical trial application was based on positive Phase 1 clinical trial results in Europe. The Phase 3 clinical program is expected to enroll over 1,300 people with diabetes
    • 14 Oct 2021 According to an Adocia media release, the Tonghua Dongbao Pharmaceutical received clearance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the Phase 3 clinical trial of BioChaperone Lispro, an Ultra-Rapid Insulin for the treatment of Type 1 and Type 2 diabetes. The first patient enrolled in the phase 3 program will trigger a milestone payment to Adocia.
    • 25 Jan 2021 According to an Adocia media release, this study is expected to commence in 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top